Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fiber snacks may ease alcohol withdrawal by healing the gut

NCT ID NCT07371286

Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether eating fiber-rich snacks (with inulin and pectin) for 28 days, alongside standard care, can improve alcohol withdrawal in adults aged 19-65 with alcohol use disorder. The goal is to reduce gut permeability and support recovery. Participants will provide blood, stool, and saliva samples and fill out questionnaires.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 138 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Feb 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women or men, * aged \>18 and ≤ 65, * French-speaking, * active alcohol users (as defined by the criteria in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, DSM-5) * who agree to be hospitalized for alcohol withdrawal for a period of 7 days * Affiliated with or eligible for social security. * Negative pregnancy test (for patients of childbearing age) Exclusion Criteria: * any other addictive disorder (except tobacco), * inflammatory bowel disease or any other chronic inflammatory disease, * current cancer, * metabolic diseases such as obesity (BMI ≥ 30 kg/m²) kg/m2) or a history of bariatric surgery, * severe cognitive impairment (MMSE \< 24), * psychiatric comorbidities including suicide risk, * cirrhosis or significant fibrosis (≥F2) defined by a Fibroscan value \>7.6 kPa, * pregnancy or breastfeeding, * taking antibiotics, probiotics, or prebiotics in the 2 months prior to inclusion, * taking non-steroidal anti-inflammatory drugs or glucocorticoids in the month prior to inclusion. * taking baclofen, disulfiram, naltrexone, or acamprosate. * Participation in another interventional study involving human subjects or being in the exclusion period following a previous study involving human subjects, if applicable * Patients under AME * Patients under guardianship, trusteeship, or any other legal protection measure

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alcohol use disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alcohol abuse

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alcohol use disorder Intestinal permeability Supplementation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.